GlaxoSmithKline Pharmaceuticals Ltd. engages in the business of manufacturing, distributing and trading in pharmaceuticals. The company's product portfolio includes prescription medicines and ...
As one of the fastest-growing major economies in the world, India has recorded a GDP growth of 7.6%* in FY 2023-24, owing to a strong rebound in economic activity. Rising disposable income levels ...
Goldman Sachs analyst Rajan Sharma maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of ...
J.P. Morgan analyst James Gordon maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Global pharma giant GlaxoSmithKline Pharmaceuticals Ltd received an income tax refund of ₹222.23 crore for the assessment year 2022-23, following an order issued by the Income Tax Department on ...
13, 2024 /PRNewswire/ -- GlaxoSmithKline Pharmaceutical Sdn Bhd (GSK) today announced the launch of its Herpes Zoster vaccine, Shingrix (MAL24056002ARZ), also known as Recombinant Zoster Vaccine ...
13, 2024 /PRNewswire/ -- GlaxoSmithKline Pharmaceutical Sdn Bhd (GSK) today announced the launch of its Herpes Zoster vaccine, Shingrix (MAL24056002ARZ), also known as Recombinant Zoster Vaccine, ...
Credit: GSK KUALA LUMPUR, Sept 10 (Bernama) -- GlaxoSmithKline Pharmaceutical Sdn Bhd (GSK) today announced the launch of the Herpes Zoster (HZ) vaccine, Shingrix, also known as Recombinant Zoster ...
Hosted on MSN18d
GlaxoSmithKline Pharmaceuticals Receives ₹222.23 Crore Tax Refund For FY 2022-23, Reports 37.8% YoY Net Profit Increase In Q1 2024GlaxoSmithKline Pharma consolidated Q1 net profit rises 9% to Rs 121 cr GlaxoSmithKline Pharmaceuticals declared a 37.8% year-on-year (YoY) increase in net profit to Rs.182.3 crore in the first ...
32 per equity share for the year. This dividend for the year ended 31 March 2024 is subject to the approval of Members at the Annual General Meeting on 28 June 2024 and will be paid on or after 1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback